Business · 14/07/2026Updated: 10/17/2026 · 1 min read
FDA Announces Final Guidance for Clinical Investigations of Psychedelic Drugs
Summary
The US Food and Drug Administration (FDA) has released a final guidance document outlining considerations for industry sponsors developing psychedelic drugs for medical conditions, following a draft issued in June 2023.
Original source language: Federal Register — Health and Human ServicesOpen original release →